Febustat

Adults:

The recommended starting dose is one Febuxostat 40 mg tablet once daily. For patients who do not achieve a serum uric acid level below 6 mg per dL after 2 weeks on Febuxostat 40 mg tablet, one Febuxostat 80 mg tablet once daily is recommended. If serum uric acid remains below 6 mg per dL after 2 to 4 weeks on Xanuric 80 (Febuxostat 80mg) tablet, then one Febuxostat 120 mg tablet once daily is recommended. For Tumor Lysis Syndrome, the recommended dose is one Febuxostat 120 mg tablet once daily. The Febuxostat 120 mg tablet should be started two days before beginning cytotoxic therapy and continued for a minimum of 7 days. Treatment may, however, be prolonged up to 9 days depending on the duration of chemotherapy, based on clinical judgment. Regarding gout flares, these may occur after starting Feboxostat tablets because changing serum uric acid levels can mobilize urate from tissue deposits. Flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended when starting Febuxostat tablets. If a gout flare occurs during treatment, Feboxostat tablets need not be discontinued; the flare should be managed concurrently, as appropriate for the individual patient. In renal impairment, no dose adjustment is necessary when giving Febuxostat to patients with mild to moderate renal impairment. In hepatic impairment, no dose adjustment is necessary in patients with mild to moderate hepatic impairment. For pediatric use, safety and effectiveness in patients under 18 years of age have not been established.